Prosthetic joint infection risk after TKA in the Medicare population

Steven M Kurtz1, Kevin L Ong, Edward Lau

  • 1Exponent, Inc, 3401 Market Street, Suite 300, Philadelphia, PA 19104, USA.

Abstract

Insights

The risk of periprosthetic joint infection (PJI) after total knee arthroplasty (TKA) is 1.55% within 2 years and 0.46% thereafter. Women and patients with comorbidities face higher risks, while hospital factors do not significantly increase PJI rates.

Area of Science:

  • Orthopedic Surgery
  • Infection Control
  • Health Services Research

Background:

  • Infection risk and contributing factors after total knee arthroplasty (TKA) require ongoing investigation due to evolving treatments.
  • Understanding these factors is crucial for improving patient outcomes and preventing complications.

Purpose of the Study:

  • To determine the incidence of deep infections following TKA in the Medicare population.
  • To identify patient-specific and hospital-related risk factors for periprosthetic joint infection (PJI) after TKA.

Main Methods:

  • Analysis of the Medicare 5% national sample administrative data from 1997-2006.
  • Longitudinal follow-up of patients undergoing TKA to identify deep infections and revision surgeries.
  • Cox regression analysis to assess patient and hospital characteristics as risk factors for PJI.

Main Results:

  • An overall infection incidence of 1.55% within 2 years and 0.46% between 2 and 10 years post-TKA was observed in 69,663 patients.
  • Female sex was associated with a lower risk of infection, while comorbidities increased the risk.
  • Patients receiving public assistance for Medicare premiums had a higher risk of PJI; hospital factors were not significant predictors.

Conclusions:

  • Periprosthetic joint infection (PJI) occurs at a significant rate in Medicare patients undergoing TKA, with the highest incidence in the first two years.
  • While most PJIs occur within two years, a substantial proportion (approximately 25%) manifest later.
  • Identifying at-risk patient populations, such as those with comorbidities or on public assistance, is vital for targeted prevention strategies.